` Comparison: GV vs ABBV - Alpha Spread

GV
vs
ABBV

Over the past 12 months, GV has underperformed ABBV, delivering a return of 0% compared to the ABBV's +9% growth.

Start AI Comparison

Smart Verdict
AI-Powered

Not Sure Which Stock Wins?
Let AI Decide.
GV
ABBV
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Smart Verdict is Ready!
See Who Stands Out.
All the numbers, charts, and metrics summarized into one smart verdict.
Stocks Compared:
Show Comparison Results
Summarizing...
We need a little more time to summarize the results

Valuation Comparison

GV Intrinsic Value
HIDDEN
Show
ABBV Intrinsic Value
HIDDEN
Show
Company Last Price Intrinsic Value DCF Value Relative Value Wall St Target
Genomic Vision SA
PAR:GV
0.0018 EUR
Abbvie Inc
NYSE:ABBV
230.63 USD
No Stocks Selected

Compare the stock's valuation with its competitors.

Select Stocks to Compare
Valuation Scenario:
Bear Case
Base Case
Bull Case

Growth Comparison

Growth Over Time
GV, ABBV

GV
ABBV
Add Stock
Revenue
www.alphaspread.com
No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare
Company LTM Historical Growth Growth Streak % Positive Years Max Drawdown Volatility Forecasted Growth
3 Years 5 Years 10 Years 1 Year 3 Years
Genomic Vision SA
Revenue
Abbvie Inc
Revenue

All metrics are calculated based on data from the last 10 years.

No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare

Profitability Comparison

Free Cash Flow
GV, ABBV

GV
ABBV
Add Stock
Free Cash Flow
www.alphaspread.com
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
Company LTM Average Historical Growth FCF Margin Conversion
3 Years 5 Years 3 Years 5 Years 10 Years
Genomic Vision SA
PAR:GV
Abbvie Inc
NYSE:ABBV
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
What is Free Cash Flow?

Gross Margin

GV
-310.1%
ABBV
71.6%
LTM 3Y Avg 5Y Avg 10Y Avg
Genomic Vision SA
Abbvie Inc

Operating Margin

GV
-789%
ABBV
34.2%
LTM 3Y Avg 5Y Avg 10Y Avg
Genomic Vision SA
Abbvie Inc

Net Margin

GV
-958.7%
ABBV
6.8%
LTM 3Y Avg 5Y Avg 10Y Avg
Genomic Vision SA
Abbvie Inc

FCF Margin

GV
-521.4%
ABBV
29.1%
LTM 3Y Avg 5Y Avg 10Y Avg
Genomic Vision SA
Abbvie Inc

ROE

GV
928.1%
ABBV
15 221.8%
LTM 3Y Avg 5Y Avg 10Y Avg
Genomic Vision SA
Abbvie Inc

ROA

GV
-243.5%
ABBV
3.1%
LTM 3Y Avg 5Y Avg 10Y Avg
Genomic Vision SA
Abbvie Inc

ROIC

GV
-561.6%
ABBV
14%
LTM 3Y Avg 5Y Avg 10Y Avg
Genomic Vision SA
Abbvie Inc

ROCE

GV
-12 578.4%
ABBV
22.4%
LTM 3Y Avg 5Y Avg 10Y Avg
Genomic Vision SA
Abbvie Inc

Solvency Comparison

No Stocks Selected

Compare company's equity waterfall with its competitors.

Select Stocks to Compare
Balance Sheet Comparison
No Stocks Selected

Compare company's balance sheet with its competitors.

Select Stocks to Compare

Stocks Performance

Stocks Performance
GV, ABBV

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
GV, ABBV

Performance Gap Between GV and ABBV
HIDDEN
Show

Performance By Year
GV, ABBV

Loading
GV
ABBV
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Not Sure Which Stock Wins?
Let AI Decide
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Compare GV to other stocks
PNEXF
Pharnext SCA
More expensive
vs GV
ATXS
Astria Therapeutics Inc
Cheaper
vs GV
AMGN
Amgen Inc
Cheaper
vs GV
GILD
Gilead Sciences Inc
Cheaper
vs GV
Unlock Full Access to Alpha Spread
Create Free Account
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett